Immunotherapy in Localized Colorectal Cancer: Current Practice and Future Directions [0.03%]
局部结直肠癌的免疫治疗：当前实践与未来方向
Evelyn Yi Ting Wong,Sheela R Damle,Kai-Keen Shiu et al.
Evelyn Yi Ting Wong et al.
Immune checkpoint inhibitors (ICIs) have fundamentally transformed the treatment landscape for localized colorectal cancer (CRC), particularly for the mismatch repair-deficient (dMMR) or microsatellite instability-high (MSI-H) subgroups. Th...
Innovation, Evidence, Compassion, and Hope: Delivering Outcomes That Matter [0.03%]
创新、证据、同理心和希望：创造有意义的价值
Samuel X Stevens,Michelle Leah Tregear,Rachel Riechelmann et al.
Samuel X Stevens et al.
Over the past 50 years, advances in systemic therapy, radiotherapy, surgery, and supportive care have dramatically improved cancer outcomes. Yet, growing concern exists that in our race for biomedical innovation, the metrics used to evaluat...
Importance of and Strategies for Implementing DPYD Testing to Prevent Severe Fluoropyrimidine Chemotherapy Toxicity in Health Care Systems [0.03%]
DPYD检测在医疗系统中预防严重氟尿嘧啶类化疗毒性的实施策略和重要性
Jeremy Kratz,Karen Merritt,Jessica Jorgensen et al.
Jeremy Kratz et al.
Recent regulatory and guideline changes have established pretreatment DPYD genotyping as a critical strategy to prevent severe fluoropyrimidine toxicity. Following earlier European leadership by the European Medicines Agency, the US Food an...
Harnessing Artificial Intelligence for the Management of Patients With GI Cancers [0.03%]
人工智能在消化系统癌症患者管理中的应用
Lipika Goyal,Caroline Chung,Yuichi Mori et al.
Lipika Goyal et al.
Artificial intelligence (AI) has the potential of reshaping GI oncology by enabling more nuanced interpretation of complex clinical, imaging, and molecular data, while supporting more timely and patient-centered decisions. This article synt...
Stage I Triple-Negative Breast Cancer: Moving From One-Size-Fits-All to a Personalized Approach [0.03%]
Dame Idossa,Maeve A Hennessy,Alexis LeVee et al.
Dame Idossa et al.
Triple-negative breast cancer (TNBC) is an aggressive breast cancer subtype characterized by lack of estrogen receptor expression, progesterone receptor expression, and human epidermal growth factor 2 overexpression/amplification. Given its...
Value, Access, and High-Quality Medical Oncology Care: Can We Have It All? [0.03%]
价值、可及性和高质量的医学肿瘤学护理：我们都能获得吗？
Ian F Tannock,Ajay Aggarwal,Haydee Verduzco-Aguirre et al.
Ian F Tannock et al.
Health systems, oncologists, and patients face a crisis in value of cancer care that has several components: interpretation of meaningful benefit, cost, and affordability that limits access to treatment and effective delivery of evidence-ba...
Tech That Scales: A Practical Framework for Artificial Intelligence-Enabled Cancer Care in Low- and Middle-Income Countries and Underserved US Counties [0.03%]
可扩展的技术：在中低收入国家和美国偏远地区启用人工智能的癌症治疗实用框架
Arturo Loaiza-Bonilla,Partha Basu,Eric Lucas et al.
Arturo Loaiza-Bonilla et al.
Cancer outcomes remain starkly unequal: 5-year survival rates for common malignancies in low- and middle-income countries (LMICs) often lag 20-40 percentage points behind high-income benchmarks, and similar disparities persist between well-...
Emerging and Established Targets in Colorectal Cancer: Translating Biology Into Therapeutics [0.03%]
colorectal cancer中新兴及成熟药物靶点：从生物学角度研发治疗手段
Rafael Grochot,Michela Bartolini,Sandra Algaze et al.
Rafael Grochot et al.
Alterations in the mitogen-activated protein kinase (MAPK) pathway play a central role in colorectal cancer (CRC) tumor biology, therapeutic response, and resistance. RAS oncogenic mutations are present in up to 35% of CRC; they represent c...
Personalizing Curative Therapy in Stage II to III Triple-Negative Breast Cancer [0.03%]
三阴性乳腺癌二期和三期治愈疗法的个性化治疗
Alexis LeVee,Maeve A Hennessy,Dame Idossa et al.
Alexis LeVee et al.
The treatment paradigm of stage II to III triple-negative breast cancer (TNBC) is rapidly evolving, with the recent incorporation of pembrolizumab to neoadjuvant chemotherapy improving disease outcomes. Nevertheless, almost one in five pati...
Dyda Dao,Katarzyna Kozak,Anne Mailhot et al.
Dyda Dao et al.
Desmoid tumors (DTs) are rare fibroblastic neoplasms driven by altered Wnt signaling pathways, through activating mutations in β-catenin (CTNNB1) or loss of repressive APC. DTs are considered as intermediate neoplasms that can be locally a...